Skip to main content

Post-herpetic Neuralgia

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
pregabalinPhase 41 trial
Active Trials
NCT00159666Completed255Est. Jun 2006
Sandoz
SandozAustria - Kundl
1 program
1
EMA401Phase 21 trial
Active Trials
NCT03094195Terminated130Est. Mar 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizerpregabalin
SandozEMA401

Clinical Trials (2)

Total enrollment: 385 patients across 2 trials

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Start: Oct 2004Est. completion: Jun 2006255 patients
Phase 4Completed

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

Start: Jun 2017Est. completion: Mar 2019130 patients
Phase 2Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.